Therma Bright Inc V.THRM

Alternate Symbol(s): TBRIF

Healthcare Medical Devices

Therma Bright Inc. is a Canada-based company, which is a developer and partner in a range of diagnostic and medical device technologies. It focuses on providing consumers and medical professionals with solutions that address medical and healthcare challenges. It is involved in developing, acquiring, manufacturing, and marketing proprietary healthcare and medical devices for the consumer and institutional marketplace. Its product offerings include Covid-19 diagnostic test product line, such as AcuVid COVID-19 Rapid Antigen Saliva Test and AcuVid COVID-19 Rapid Antibody Test; Sores & Bite Inflammation Therapy product line, such as InterceptCS Cold Sore Prevention System and TherOZap, and Muscle Pain & Blood Circulation Health Therapy product line, such as Venowave, which is a circulation booster designed to improve circulation in the lower extremities. Its products include Benepod, Inretio, AI4LYF, Invixa and Instatin, and others.

TSXV:THRM - Post by User

Therma Bright Inc > Cross Reactivity

<< Previous

Bullboard Posts

Next >>

Comment by Moemoney42on Oct 15, 2021 9:43am

69 Views

Post# 34008949

RE:RE:RE:Cross Reactivity

LOL.. that's right moron.. attack the poster, not the facts eh... you're a clown..!

Kaiser wrote:
if anyone was curious about Moes credentials he's not only a big oil tycoon but a scientist as well. lol

What a pos you are Moe. Remember when you were pumping Sona? LOLOLOLOLOLOLOL!!!

Moemoney42 wrote: Although that's a nice smoke and mirrors effort at explaining why the FDA hasn't cleared the test its fundamentally wrong.. an antigen test does not test for "antigens of othe respiratory viruses" it tests for "proteins" in the virus... but nice try at clouding the issue.. LOL..

Smokey1958 wrote: From what I can gather, based on Robs' most recent interview, the holdup with the FDA is they want to make sure AcuVid does not detect the antigens of other respiratory viruses that would lead to false results. I'm not sure I've read anywhere of that being a neccessity for other authorized tests but it is highly unlikely that others would have been able to sidestep this issue. The reason for this, as an example, is that at an early age we are all getting infected by and creating antibodies for the most prevalent coronavirus ...the common cold.

The challenge, which I expect is just one of time, is to access other viral antigens (?)and to carry out the tests to make sure the test (the assay of the test which is antigen specific) that would be protein specific is not being influenced by or reacting to the antigens of other coronaviruses. Nope wrong again.

To me this suggests good news and that AcuVid has met all other criterion and this is merely the last step to insure the accuracy of AcuVid and in doing so make way for authorization. Imho the other reason that AcuVid is in line for authorization is that there has been NO PROBLEM thus far of it detecting variants. That means the assay choice was one that detects antigens that are common to all the variants. Nope..! With such a strong showing thus far it's hard to imagine AcuVid not being able to detect future variants.

GLTE ...holding patiently!!! An NR based on the CE mark would be timely right about now!!!